journal article·2023-09Open access

Polymeric nanoparticle gel for intracellular mRNA delivery and immunological reprogramming of tumors

Sarah Y. Neshat, Chun Hei Ryan Chan, Jawaun Harris, Osamah M. Zmily, Savannah Est-Witte, Johan Karlsson, Sydney R. Shannon, Manav Jain, Joshua C. Doloff, Jordan J. Green, Stephany Y. Tzeng

Biomaterials· Volume 300

Abstract

Immuno-oncology therapies have been of great interest with the goal of inducing sustained tumor regression, but clinical results have demonstrated the need for improved and widely applicable methods. An antigen-free method of cancer immunotherapy can stimulate the immune system to recruit lymphocytes and produce immunostimulatory factors without prior knowledge of neoantigens, while local delivery reduces the risk of systemic toxicity. To improve the interactions between tumor cells and cytotoxic lymphocytes, a gene delivery nanoparticle platform was engineered to reprogram the tumor microenvironment (TME) in situ to be more immunostimulatory by inducing tumor-associated antigen-presenting cells (tAPCs) to activate cytotoxic lymphocytes against the tumor. Biodegradable, lipophilic poly (beta-amino ester) (PBAE) nanoparticles were synthesized and used to co-deliver mRNA constructs encoding a signal 2 co-stimulatory molecule (4-1BBL) and a signal 3 immuno-stimulatory cytokine (IL-12), along with a nucleic acid-based immunomodulatory adjuvant. Nanoparticles are combined with a thermoresponsive block copolymer for gelation at the injection site for local NP retention at the tumor. The reprogramming nanoparticle gel synergizes with immune checkpoint blockade (ICB) to induce tumor regression and clearance in addition to resistance to tumor rechallenge at a distant site. In vitro and in vivo studies reveal increases in immunostimulatory cytokine production and recruitment of immune cells as a result of the nanoparticles. Intratumoral injection of nanoparticles encapsulating mRNA encoding immunostimulatory agents and adjuvants via an injectable thermoresponsive gel has great translational potential as an immuno-oncology therapy that can be accessible to a wide range of patients.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Immunotherapy and Immune Responses · CAR-T cell therapy research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (77)

Show source-provided references
1. Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways
2. Cancer immunotherapy: challenges and limitations10.1016/j.prp.2021.153723 ↗
3. Immunotherapy and tumor microenvironment10.1016/j.canlet.2015.10.009 ↗
4. Cytotoxic CD8+ T cells in cancer and cancer immunotherapy
5. Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges10.1038/s41571-019-0308-z ↗
6. Engineered T cells: the promise and challenges of cancer immunotherapy10.1038/nrc.2016.97 ↗
7. Nanoscale artificial antigen presenting cells for cancer immunotherapy10.1016/j.molimm.2018.02.016 ↗
8. Scaffolds that mimic antigen-presenting cells enable ex vivo expansion of primary T cells10.1038/nbt.4047 ↗
9. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines10.1038/s41571-020-00460-2 ↗
10. Identification of neoantigens for individualized therapeutic cancer vaccines10.1038/s41573-021-00387-y ↗
11. Engineering precision nanoparticles for drug delivery
12. Gene delivery for immunoengineering10.1016/j.copbio.2020.05.008 ↗
13. Targeting strategies for mRNA delivery
14. Delivery technologies for genome editing10.1038/nrd.2016.280 ↗
15. | Xiang Gao, Nonviral vector system for cancer immunogene therapy. MedComm – biomater
16. Toward gene transfer nanoparticles as therapeutics10.1002/adhm.202102145 ↗
17. PEGylation of poly(amine-co-ester) polyplexes for tunable gene delivery10.1016/j.biomaterials.2021.120780 ↗
18. In situ genetic engineering of tumors for long-lasting and systemic immunotherapy10.1073/pnas.1916039117 ↗
19. High-throughput and high-content bioassay enables tuning of polyester nanoparticles for cellular uptake, endosomal escape, and systemic in vivo delivery of mRNA10.1126/sciadv.abk2855 ↗
20. Costimulatory ligand 4-1BBL (CD137L) as an efficient adjuvant for human antiviral cytotoxic T cell responses10.1073/pnas.0306567101 ↗
21. 4-1BB costimulation promotes bystander activation of human CD8 T cells10.1002/eji.202048762 ↗
22. IL-12 produced by dendritic cells augments CD8+ T cell activation through the production of the chemokines CCL1 and CCL1710.4049/jimmunol.181.12.8576 ↗
23. Upregulation of class I major histocompatibility complex antigens by interferon gamma is necessary for T-cell-mediated elimination of recombinant adenovirus-infected hepatocytes in vivo10.1073/pnas.92.16.7257 ↗
24. Antigen presentation by MHC class I and its regulation by interferon γ10.1016/S0952-7915(99)80014-4 ↗
25. Roles of IFN-γ in tumor progression and regression: a review
26. Localized interleukin-12 for cancer immunotherapy10.3389/fimmu.2020.575597 ↗
27. Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin’s lymphoma and Hodgkin's disease10.1158/1078-0432.CCR-04-0540 ↗
28. Activity of subcutaneous interleukin-12 in AIDS-related Kaposi sarcoma10.1182/blood-2005-11-4455 ↗
29. Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma
30. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production
31. Interleukin 12: still a promising candidate for tumor immunotherapy? Cancer Immunol
32. Targeting toll-like receptors for cancer therapy10.1007/s11523-018-0589-7 ↗
33. TLR agonists as vaccine adjuvants targeting cancer and infectious diseases
34. Polymeric nanoparticles encapsulating novel TLR7/8 agonists as immunostimulatory adjuvants for enhanced cancer immunotherapy10.1016/j.biomaterials.2018.02.034 ↗
35. CpG oligodeoxynucleotides as immunotherapy in cancer10.1016/j.uct.2007.11.003 ↗
36. Cationic polymers for enhancing CpG oligodeoxynucleotides-mediated cancer immunotherapy10.1016/j.eurpolymj.2018.12.044 ↗
37. Jin · Development of CpG oligodeoxynucleotide TLR9 agonists in anti-cancer therapy · 2021 · 841
38. Polymersome-mediated cytosolic delivery of cyclic dinucleotide STING agonist enhances tumor immunotherapy
39. STINGel: controlled release of a cyclic dinucleotide for enhanced cancer immunotherapy10.1016/j.biomaterials.2018.01.035 ↗
40. The age of cyclic dinucleotide vaccine adjuvants10.3390/vaccines8030453 ↗
41. Biodegradable STING agonist nanoparticles for enhanced cancer immunotherapy10.1016/j.nano.2017.10.013 ↗
42. Poly-IC enhances the effectiveness of cancer immunotherapy by promoting T cell tumor infiltration10.1136/jitc-2020-001224 ↗
43. Combined adjuvant of poly I:C improves antitumor effects of CAR-T cells10.3389/fonc.2019.00241 ↗
44. Light-controllable charge-reversal nanoparticles with polyinosinic-polycytidylic acid for enhancing immunotherapy of triple negative breast cancer10.1016/j.apsb.2021.06.006 ↗
45. Anticancer function of polyinosinic-polycytidylic acid10.4161/cbt.10.12.13450 ↗
46. Injectable drug depot engineered to release multiple ophthalmic therapeutic agents with precise time profiles for postoperative treatment following ocular surgery10.1016/j.actbio.2018.04.037 ↗
47. mRNA structure regulates protein expression through changes in functional half-life10.1073/pnas.1908052116 ↗
48. Effects of chemically modified messenger RNA on protein expression10.1021/acs.bioconjchem.6b00090 ↗
49. Chemical modification of uridine modulates mRNA-mediated proinflammatory and antiviral response in primary human macrophages10.1016/j.omtn.2022.01.004 ↗
50. Unleashing TNF cytotoxicity to enhance cancer immunotherapy10.1016/j.it.2021.10.003 ↗
51. The role of IL-27 in the induction of anti-tumor cytotoxic T lymphocyte response
52. Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy10.18632/oncotarget.19531 ↗
53. Charge-altering releasable transporters (CARTs) for the delivery and release of mRNA in living animals10.1073/pnas.1614193114 ↗
54. Enhanced mRNA delivery into lymphocytes enabled by lipid-varied libraries of charge-altering releasable transporters10.1073/pnas.1805358115 ↗
55. mRNA vaccination with charge-altering releasable transporters elicits human T cell responses and cures established tumors in mice10.1073/pnas.1810002115 ↗
56. 2022
57. 2022
58. Durable anticancer immunity from intratumoral administration of IL-23, IL-36γ, and OX40L mRNAs10.1126/scitranslmed.aat9143 ↗
59. Novel jet-injection technology for nonviral intratumoral gene transfer in patients with melanoma and breast cancer10.1158/1078-0432.CCR-08-0412 ↗
60. The systemic administration of Ig-4-1BB ligand in combination with IL-12 gene transfer eradicates hepatic colon carcinoma10.1038/sj.gt.3302556 ↗
61. Rejection of disseminated metastases of colon carcinoma by synergism of IL-12 gene therapy and 4-1BB costimulation10.1006/mthe.2000.0086 ↗
62. Long-term proliferation of functional human NK cells, with conversion of CD56(dim) NK cells to a CD56 (bright) phenotype, induced by carcinoma cells co-expressing 4-1BBL and IL-1210.1007/s00262-011-1122-3 ↗
63. The toxicology of interleukin-12: a review10.1177/019262339902700112 ↗
64. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies
65. Intratumoral delivery of immunotherapy—act locally, think globally10.4049/jimmunol.1601145 ↗
66. Intratumoral injection of IL-12 plasmid DNA--results of a phase I/IB clinical trial10.1038/sj.cgt.7701064 ↗
67. 2022
68. Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients10.1016/j.annonc.2019.12.008 ↗
69. 2022
70. 2022
71. 2022
72. Intratumoral DNA-based delivery of checkpoint-inhibiting antibodies and interleukin 12 triggers T cell infiltration and anti-tumor response10.1038/s41417-021-00403-8 ↗
73. 2022
74. Tavo · 2022
75. 2022
76. Clinical potential of electroporation for gene therapy and DNA vaccine delivery10.1517/17425247.2016.1121990 ↗
77. Electroporation for the delivery of DNA-based vaccines and immunotherapeutics: current clinical developments10.1038/mt.2009.5 ↗